GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RayzeBio inc (NAS:RYZB) » Definitions » Return-on-Tangible-Asset

RayzeBio (RayzeBio) Return-on-Tangible-Asset : -16.00% (As of Sep. 2023)


View and export this data going back to 2023. Start your Free Trial

What is RayzeBio Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. RayzeBio's annualized Net Income for the quarter that ended in Sep. 2023 was $-72.76 Mil. RayzeBio's average total tangible assets for the quarter that ended in Sep. 2023 was $454.64 Mil. Therefore, RayzeBio's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2023 was -16.00%.

The historical rank and industry rank for RayzeBio's Return-on-Tangible-Asset or its related term are showing as below:

RYZB' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -25.35   Med: -16.14   Max: -4.66
Current: -8

During the past 3 years, RayzeBio's highest Return-on-Tangible-Asset was -4.66%. The lowest was -25.35%. And the median was -16.14%.

RYZB's Return-on-Tangible-Asset is not ranked
in the Biotechnology industry.
Industry Median: -40.42 vs RYZB: -8.00

RayzeBio Return-on-Tangible-Asset Historical Data

The historical data trend for RayzeBio's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RayzeBio Return-on-Tangible-Asset Chart

RayzeBio Annual Data
Trend Dec20 Dec21 Dec22
Return-on-Tangible-Asset
-4.66 -16.14 -25.35

RayzeBio Quarterly Data
Dec20 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23
Return-on-Tangible-Asset Get a 7-Day Free Trial - - -18.11 - -16.00

Competitive Comparison of RayzeBio's Return-on-Tangible-Asset

For the Biotechnology subindustry, RayzeBio's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RayzeBio's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RayzeBio's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where RayzeBio's Return-on-Tangible-Asset falls into.



RayzeBio Return-on-Tangible-Asset Calculation

RayzeBio's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2022 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=-68.6/( (216.385+324.776)/ 2 )
=-68.6/270.5805
=-25.35 %

RayzeBio's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Sep. 2023 )  (Q: Jun. 2023 )(Q: Sep. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Sep. 2023 )  (Q: Jun. 2023 )(Q: Sep. 2023 )
=-72.764/( (305.762+603.513)/ 2 )
=-72.764/454.6375
=-16.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Sep. 2023) net income data.


RayzeBio  (NAS:RYZB) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


RayzeBio Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of RayzeBio's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


RayzeBio (RayzeBio) Business Description

Traded in Other Exchanges
N/A
Address
5505 Morehouse Drive, Suite 300, San Diego, CA, USA, 92121
RayzeBio inc is a company operating as vertically integrated radiopharmaceutical therapeutics company. The main objective of the company is defeating cancer with radiopharmaceutical medicines. It has a created a pipeline of multiple drug candidates, in therapeutic areas with significant market opportunities. They have a portfolio of potential RPT drug and development candidates that includes late-stage clinical programs, development programs and discovery programs.
Executives
Hauwermeiren Timothy Van director C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Maha Katabi director SOFINNOVA INVESTMENTS, 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Viking Global Opportunities Drawdown Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Drawdown Portfolio Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Arvind Kush officer: Chief Financial Officer C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121
Wellington Biomedical Innovation Master Investors (cayman) Ii L.p. 10 percent owner 280 CONGRESS STREET, BOSTON MA 02210
Versant Ventures Vii Gp-gp, Llc 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Ventures Vii Gp, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Kenneth Song director, officer: President and Chief Executive C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121
Susan Moran officer: Chief Medical Officer 1232 RICHARDSON AVE, LOS ALTOS CA 94024
Venbio Global Strategic Gp Iii, L.p. 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Venbio Global Strategic Gp Iii, Ltd 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCI CA 94158
Venbio Global Strategic Fund Iii, L.p. 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Redmile Biopharma Investments Ii, L.p. 10 percent owner LETTERMAN DIGITAL ARTS CENTER, ONE LETTERMAN DRIVE, SUITE D3-300, SAN FRANCISCO CA 94129